I kontrollerede kliniske forsøg er hyppigheden af rapporteret hjerteinsufficiens ved pioglitazonbehandling den samme som for placebo -, metformin - og sulfonylurinstof- grupperne.
In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups.